Biotech Finds Mid-Week Success Following Q4 Earnings Release

Biotech Finds Mid-Week Success Following Q4 Earnings Release

Biotech Finds Mid-Week Success Following Q4 Earnings Release By: Dylan Sikes – AllPennyStocks.com News

Wednesday, March 13, 2024

A California-based biotech company saw its shares soar on Wednesday, a day following the company’s Q4 earnings announcement. With analysts expecting a net loss of $0.16 per diluted share, Heron Therapeutics Inc. (Nasdaq:HRTX) Q4 results came in at a net loss of $0.07 per diluted share.

Traders naturally were optimistic on the better-than-expected results as shares traded up to $3.22/share (+36.44%) at the early session high. This move occurred in tandem with the biotech sector as a whole finding success as of late.

Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of SUSTOL, ZYNRELEF, and CINVANTI. Its pipeline product is HTX-011.


Copyright © 2024 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canadian Manufacturing and Wholesale Sales Point to Weakening Economy and Raise Possibilities of Rate Cuts
Drill Less, Extract More: This Just Announced Merger Unlocks Profits
100,000,000 Euro Commitment Sends Shares of this MicroCap Hydrogen Automaker Soaring
Most Popular
FREE Newsletter
AllPennyStocks.com Favorites


Back to Top